Aims: This study examined whether chronic treatment with losartan, an angiotensin II type 1 receptor (AT 1 R) antagonist, might reverse COX-2-mediated vascular dysfunction in mesenteric resistance arteries (MRA) from offspring of hyperglycaemic rats. Materials and methods: Male 12-month-old offspring of hyperglycaemic (O-DR) and normoglycaemic (O-CR) rats were treated with losartan (15 mg·kg·day
Introduction
Epidemiological and experimental studies have demonstrated that adverse environment experienced in utero during the critical period of development may negatively influence metabolic and cardiovascular health in later life, a phenomenon called fetal programming [1] . Studies using animals exposed in utero to maternal hyperglycemia have shown the occurrence of obesity, insulin resistance, type-2 diabetes, hypertension and vascular disorders in adulthood [2] [3] [4] . In fact, results from our group have demonstrated that hyperglycemia during pregnancy promotes insulin resistance and remarkable functional vascular changes in adult offspring that possibly contribute to elevated blood pressure (BP) in these rats [5] [6] [7] [8] . These vascular abnormalities were characterized by impaired endothelium-dependent vasodilation and increased adrenoceptor-mediated vasoconstriction, which were related to cyclooxygenase (COX)-2 up-regulation [6] [7] [8] .
In the arterial wall, COX-2 is usually expressed at undetectable levels but it can be up-regulated by inflammatory, mitogenic and physical stimuli [9] . Enhanced vascular COX-2 expression has been reported in several pathological conditions associated with cardiovascular risk, such as obesity [10] , type-2 diabetes [11] , hypertension [12] , hyperaldosteronism [13] and atherosclerosis [14] . Moreover, some authors have reported a role for contractile COX-2-derived prostanoids in both the endothelial dysfunction and in the vascular contractile responses, observed with hypertension, diabetes or obesity [10] [11] [12] [13] .
In several tissues, angiotensin II (Ang II) is a potent COX-2 expression inducer. In the glomeruli from rat kidneys, this peptide induced a six-fold increase in COX-2 expression; in mesangial cells the PGE 2 and PGI 2 release increased 200% and 100% in response to Ang II, respectively [15] . Increased COX-2 expression was also reported in Ang II-stimulated vascular cells, including fibroblasts, smooth muscle and endothelial cells [16] [17] [18] . In hypertensive or diabetic animals, the COX-2-dependent vascular disorders have also been attributed, at least in part, to Ang II [12, 19, 20] . This effect seems to be mediated by Ang II type 1 receptor (AT 1 R) activation, since it has been inhibited by AT 1 R antagonists [12, 15, 20, 21] .
In a previous report, we have described that COX-2 expression is greater in mesenteric resistance arteries (MRA) from offspring of hyperglycaemic rats than in offspring of control rats [6] . This COX-2 overexpression was accompanied by increased contractile prostanoid release that impaired endothelium-dependent vasodilation and increased noradrenaline vasoconstriction [6] [7] [8] . Based on these findings, and considering that increased angiotensin converting enzyme (ACE) activity was reported in several tissues from offspring of hyperglycaemic rats [22] , we hypothesized that COX-2-dependent vascular changes observed in our previous studies may involve the participation of Ang II.
Thus, the purpose of this study was to extend our previous results and to investigate whether chronic treatment with losartan, an AT 1 R antagonist, might reverse COX-2-mediated vascular dysfunction in MRA from offspring of hyperglycaemic rats.
Material and methods
All procedures used in this study were performed in accordance with guidelines of the Ethical Principles in Animal Research adopted by the Brazilian College for Animal Experimentation and was approved by the Committee for Ethics in Animal Experimentation of the Universidade Federal de Pernambuco (UFPE) (protocol number: 23076.031785/2012-26). Wistar rats from colonies maintained at the Animal Quarters of UFPE were housed in individually ventilated cages (425 mm × 266 mm × 185 mm; Tecniplast, Buguggiate, Italy) with three animals in each cage. The room where they were kept had a 12 h-12 h light-dark cycle, and the temperature was regulated within the range of 22-24°C. Rats had free access to tap water and standard rat chow ad libitum (Labina, Agribands Purina, São Paulo, Brazil).
Animals
On the 7th day of pregnancy, hyperglycemia was induced by a single injection of streptozotocin (STZ; 50 mg/kg of body weight in 10 mmol/L citrate buffer, pH 4.5) (Sigma-Aldrich, St. Louis, MO) [6] [7] [8] . Pregnant rats were also injected with only vehicle for STZ administration (citrate buffer) and considered as control group. To confirm the hyperglycemia during pregnancy (ACCU-CHEK®, Roche Diagnostics, Mannheim, Germany), maternal blood was collected on day 14 of gestation from a blood sample from the tail vein. All diabetic dams included in the study had the fasting blood glucose levels between 250 and 500 mg/dL. After birth, each litter was reduced to six pups and restricted to male offspring only. When the male number was not enough to complete six, females were used but sacrificed at weaning.
Because vascular changes in offspring of hyperglycaemic rats worsen with age, being higher at 12 months after birth [6] [7] [8] , in this work we chose to study 12-month-old offspring. These rats were divided into four groups: O-CR (offspring of control rats), O-DR (offspring of hyperglycaemic rats), O-CR-los (losartan-treated O-CR) and O-DR-los (losartan-treated O-DR). Treatment with losartan (15 mg·kg·day − 1 by gavage for 2 months) was initiated in rats with 10 months of age. Each experiment was carried out with offspring from at least three different litters.
Insulin tolerance test
The insulin tolerance test (ITT) was performed according to a standard protocol. After a ten-hour fast, a single intraperitoneal dose (1.5 U·kg − 1 of body weight) of insulin was injected. Blood glucose was determined (ACCU-CHEK®, Roche Diagnostics, Mannheim, Germany) before and after 15, 30, 45 and 60 min of insulin administration from a blood sample from the tail vein.
Arterial BP measurement
For BP measurements, offspring were anesthetized with ketamine and xylazine mixture (80 mg·kg −1 and 5 mg·kg
, respectively, i.p.). A polyethylene catheter (PE-50, Clay Adams, Parsippany, NJ, USA) was inserted into the right carotid artery for direct arterial pressure measurement. The distal end of the catheter was tunneled subcutaneously, exteriorized in the mid scapular region and sutured to the skin, which allows the rat freedom of movement. At the end of the surgery, intramuscular injection of the analgesic and anti-inflammatory ketoprofen (5 mg·kg −1 , i.m., Venco Laboratory, Londrina, Brazil) was performed. Animals were allowed free access to food and water. After 24 h, BP was measured in conscious animals by a pressure transducer (MLT0380; ADInstruments Pty Ltd., Castle Hill, New South Wales, Australia) connected to an amplifier (Bridge Amp, ML224; ADInstruments) and an acquisition system (PowerLab 4/30, ML866; ADInstruments), and the signals were digitized with appropriate software (Chart Pro; ADInstruments). Heart rate (HR) was derived from the pulsatile BP signal. The cardiovascular parameters were recorded for 60 min, but only the last 30 min were considered for data analysis. To avoid possible influence of the surgical process on the vascular reactivity, these animals were not used for additional experiments. After BP measurement, rats were anesthetized (ketamine and xylazine mixture) and killed by decapitation.
Vascular reactivity study
In a separate group of animals MRA reactivity were assessed using methods previously described [6] [7] [8] 23] . Rats were anesthetized with ketamine and xylazine mixture and killed by exsanguination. The mesenteric vascular bed was removed and placed in cold (4°C) KrebsHenseleit solution (KHS; in mmol/L: 115 NaCl, 2. For reactivity experiments, the third-order branch of the mesenteric arcade was dissected and cut into segments of approximately 2 mm in length. Segments of MRA were mounted between two tungsten wires (40 μm diameter) in a small vessel chamber myograph (Danish Myo Technology A/S, Aarhus, Denmark) to measure isometric tension according to Mulvany and Halpern [23] . After a 15-min equilibration period in oxygenated KHS (95% O 2 and 5% CO 2 ) at 37°C and pH 7.4, segments were stretched to their optimal lumen diameter for active tension development. This was determined based on the internal circumference/wall tension ratio of the segments by setting their internal circumference, L 0 , to 90% of what the vessels would have been if they were exposed to a passive tension that was equivalent to the tension produced by a transmural pressure of 100 mm Hg. The internal diameter (I 1 ) was determined according to the equation I 1 = L 1 / π, using specific software for normalization of resistance arteries (DMT Normalization Module, ADInstruments).
Experimental protocols
At the beginning of each experiment, arteries were challenged with 120 mmol/L KCl (KPSS) to test vessel viability. After a washout period, the presence of the vascular endothelium was confirmed by the ability of 1 μmol/L acetylcholine to relax segments precontracted with 10 μmol/L noradrenaline. The segments were rinsed with KHS for 1 h and then a cumulative acetylcholine concentration-response curve (0.1 nmol/L to 3 μmol/L) was obtained in the noradrenaline precontracted segments. After 60 min, cumulative concentration-response curves for noradrenaline (10 nmol/L to 30 μmol/L) were generated.
The possible role of COX-derived metabolites on acetylcholine and noradrenaline responses was investigated in segments pre-treated with either indomethacin (a COX-1 and COX-2 inhibitor, 10 μmol/L) or NS-398 (a selective COX-2 inhibitor, 10 μmol/L). In another set of experiments, acetylcholine and noradrenaline curves were performed in presence of the NO synthase inhibitor L-NAME (100 μmol/L) or the permeable superoxide dismutase mimetic tempol (10 μmol/L). Each drug was added 30 min before the concentration-response curves.
Western blot analysis
COX-2 protein level was quantified using immunoblot analysis procedures. Mesenteric arterial tissues were homogenized; proteins were electrophoretically separated (30 μg per lane) and transferred to polyvinyl difluoride membranes (GE Healthcare do Brasil Ltda, São Paulo, SP, Brazil). Membranes were incubated with antibodies (Cayman Chemical Company, Ann Arbor, Michigan, U.S.A.) against COX-2 (1:500 dilution) or α-actin (1:3000 dilution) proteins and individual horseradish peroxidase-conjugated secondary antibodies (GE Healthcare do Brasil Ltda, São Paulo, SP, Brazil) in blocking buffer. Immunoreactive proteins were detected by chemiluminescence with ECL Plus (GE Healthcare do Brasil Ltda, São Paulo, SP, Brazil). The chemiluminescent signals were captured using ChemiDoc XRS imaging system (Bio-Rad Laboratories, Hercules, CA, USA) and was quantified with Image Lab Software™ version 5.2 (Bio-Rad Laboratories, Hercules, CA, USA). COX-2 specific signals in each lane were normalized to the actin signal. Mouse Prostanoid release was measured as in our previous studies [6] [7] [8] 13] . To allow us to measure this release, the second, third and fourth branches of mesenteric artery were carefully cleaned of fat and connective tissue. These were placed for 45 min in tubes containing 200 μL of gassed KHS at 37°C. Afterward, three 10-min washout periods were run and the medium (200 μL) was collected to measure basal TxA 2 , PGE 2 and PGF 2α . Once the chamber was refilled, acetylcholine (0.1 nM to 3 μM) or noradrenaline (10 nmol/L to 30 μmol/L) was cumulatively applied at 2-min intervals. After the mesenteric segments had been removed, the tubes were freeze clamped in liquid nitrogen and stored at −80°C for later analysis. Prostaglandins were measured using a commercially available enzyme immunoassay (EIA) kit (Cayman Chemical Company, Ann Arbor, Michigan, U.S.A.). The different assays were performed following manufacturer instructions. Results were expressed as pg·mL −1 mg wet tissue −1 .
Statistical analysis
All the results were expressed as mean ± SEM of the number of rats used in each experiment. Differences were analyzed using Student's ttest, one way or two-way ANOVA. When ANOVA showed a significant treatment effect, Bonferroni's post hoc test was used to compare individual's means (GraphPad Prism Software, San Diego, CA, U.S.A.). Differences were considered statistically significant at p b 0.05. Results from the ITT demonstrated significant insulin resistance among the O-DR rats, as they presented a higher blood glucose from 30 min to 60 min after insulin injection (Fig. 1A) . In O-DR, insulin sensitivity was improved after treatment with losartan (Fig. 1A) . However, there were no significant differences in this parameter between the losartan-treated and untreated O-CR (Fig. 1A) .
Results

Effects of losartan
In O-DR, the BP was~36% higher than O-CR (Fig. 1B) . The treatment with losartan reduced BP to a normotensive level in O-DR, whereas did not affect it in O-CR (Fig. 1B) . The HR was similar in all groups studied (data not shown). Acetylcholine induced endothelium-dependent vasodilator responses that were markedly impaired in arteries from O-DR than O-CR ( Fig. 2A and B) . Losartan treatment did not affect vasodilation to acetylcholine in O-CR, but increased it in O-DR MRA ( Fig. 2A and B) . The vasodilation to the NO donor sodium nitroprusside was similar in all groups (Fig. 2C) . The non-selective COX inhibitor indomethacin and the selective COX-2 inhibitor NS-398 increased relaxation to acetylcholine in segments from O-DR, but not from O-CR (Fig. 3A and B) , as described previously [6] . Losartan treatment abolish the inhibitory effect of these drugs only in arteries O-DR (Fig. 3D) . The NO synthase inhibitor L-NAME reduced acetylcholine-induced relaxation in arteries from O-CR and O-DR, but to a lesser extent in O-DR MRA (Fig. 4) . Incubation with the permeable superoxide mimetic tempol increased the vasodilation response to acetylcholine only in O-DR (Fig. 4) .
Effects of losartan treatment on vascular function
The contractile response to noradrenaline was greater in arteries from O-DR than O-CR rats (Fig. 5 ). The treatment with losartan reduced this response to a similar level observed in O-CR (Fig. 5) . Losartan treatment did not affect the vasoconstriction to noradrenaline in O-CR group (Fig. 5) . In MRA from O-DR, incubation with either indomethacin or NS-398 decreased the contractile response to noradrenaline only in O-DR (Fig. 6) . Losartan treatment decreased abolish the inhibitory effect of these COX inhibitors in MRA from O-DR (Fig. 6D) . L-NAME increased the response to noradrenaline in arteries from O-CR and failed to produce significant increases of noradrenaline-induced contraction in O-DR MRA (Fig. 7) . Losartan treatment restored the response to the L-NAME added to the O-DR MRA (compared Fig. 7A with D) . Incubation with tempol decreased vasoconstriction to noradrenaline only in untreated O-DR (Fig. 7) .
Effects of losartan treatment on COX-2 expression and prostanoids production
As previously reported [6] , COX-2 expression was greater in MRA from O-DR than age-matched O-CR (Fig. 8A) . After losartan treatment, there was no difference on COX-2 expression between O-CR and O-DR (Fig. 8B) .
Basal and acetylcholine-or noradrenaline-stimulated TxA 2 ( Fig. 8C ), PGE 2 (Fig. 8D ) and PGF 2α (Fig. 8E) were increased in arteries from O-DR than O-CR. Losartan treatment decreased the release of these prostanoids into the incubation medium from O-DR, but it did not modify these levels in O-CR (Fig. 8 ).
Discussion
In this study, we have demonstrated that chronic administration of the AT 1 R antagonist losartan decreased BP, improved insulin sensitivity and reversed endothelial dysfunction in adult offspring of hyperglycaemic rats (O-DR). By inhibiting COX-2 expression and decreasing contractile prostanoids release, losartan improved the endothelium-dependent vasodilation and decreased the vasoconstriction to noradrenaline in MRA from O-DR. Taken together these results suggest a role for Ang II as a putative mediator of hyperglycemia-programmed vascular dysfunction in rats.
Exposure to hyperglycemia in utero is a significant risk factor for development of metabolic syndrome components, including type-2 diabetes, obesity and hypertension [2, 4] . In these pathological conditions, the renin angiotensin system plays an important role in the initiation and progression of metabolic and cardiovascular abnormalities. In the current study, chronic treatment with the AT 1 R antagonist losartan reduced blood glucose levels during ITT in O-DR, which is consistent with an improvement of insulin sensitivity. In different insulin resistant models, other investigators have also described increased insulin sensitivity after AT 1 R blockade [24] [25] [26] . Several mechanisms have been proposed to explain how Ang II induces insulin resistance. It has been reported that this peptide decreases the insulin receptor substrate (IRS)-1 phosphorylation and inhibits the glucose transporter (GLUT-4) translocation through cell membrane [27] . In the pancreatic islets, Ang II induces β-cells dysfunction by decreasing islet blood flow and by promoting oxidative stress, inflammation and fibrosis [27] . Moreover, in the skeletal muscle this peptide decreases microvascular blood flow, which may represent an additional mechanism for the Ang II-induced insulin resistance [27] . The results of the present study along with the fact that maternal hyperglycemia increases tissue ACE activity in adult offspring [22] suggest a role for Ang II as an insulin resistance inducer in O-DR.
The treatment with losartan significantly decreased BP in O-DR, abolishing the differences between O-DR and O-CR. There are several mechanisms that may explain the antihypertensive effect of losartan in O-DR; one of them is the blockade of Ang II actions in the vasculature. In the vascular system, Ang II induces vasoconstriction, stimulates hyperplasia and hypertrophy of smooth muscle and induces vascular fibrosis [28] . Moreover, Ang II has potent proinflammatory actions in the vascular wall, including the production of reactive oxygen species (ROS) and inflammatory cytokines that contribute to the onset and progression of endothelial dysfunction [28] . To judge from this body of evidence, the improvement of the endothelium-mediated responses seen in the present losartan-treated O-DR may be associated with the lowering of BP that results from a sustained blockade of the AT 1 R.
The present and previous results [6, 7] demonstrate that the endothelium-dependent relaxation is impaired and the vasoconstriction to alpha-adrenergic stimulation is increased in MRA from O-DR. Both parameters were related to COX-2 up-regulation and increased contractile prostanoids release (TxA 2 , PGE 2 and PGF 2α ) [6, 7] . In several tissues, including the arterial wall, Ang II is a potent COX-2 expression inducer. Thus, in vascular fibroblasts [17] smooth muscle [21] and endothelial cells [18] , Ang II upregulates COX-2 expression through the activation of AT 1 R [16, 21] . Moreover, in hypertensive or diabetic animals, the COX-2-dependent vascular disorders have also been attributed, at least in part, to Ang II [12, 19, 20] . Considering these results and the fact that offspring of hyperglycaemic dams have increased tissue ACE activity [22] , we hypothesized that Ang II could be involved in hyperglycemia-programmed vascular dysfunction in adult offspring. Indeed, a novel, potentially important finding of the present study is that chronic losartan administration normalized both the impaired endothelium-dependent vasodilation and the enhanced vasoconstriction seen in O-DR MRA. In these arteries, losartan treatment 1) normalized acetylcholine relaxation; 2) decreased noradrenaline vasoconstriction; 3) abolished the effect of indomethacin or NS-398 on acetylcholine and noradrenaline responses in O-DR; 4) reversed the COX-2 protein overexpression and 5) reduced the increased acetylcholine-and noradrenaline-stimulated TxA 2 , PGE 2 and PGF 2α found in O-DR. Evidences from some other models support the above findings. For example, a) AT 1 R activation by Ang II increased COX-2 expression and contractile prostanoids that are involved in phenylephrine responses in aorta from spontaneously hypertensive rats [12] ; b) losartan treatment of type 2 diabetic rats suppressed both contraction and prostanoid release in their mesenteric arteries [20] and c) Ang II increases cPLA 2 activity in vascular smooth muscle cells [29] as well as both COX-2 expression in aortic fibroblasts from normotensive and hypertensive rats through AT 1 R [17] . Together, the previous evidences and the present data suggest that losartan normalizes hyperglycemia-programmed vascular dysfunction via suppression of the COX-2 pathway.
Interactions between COX-2 and ROS have been reported in many experimental conditions [9, 10, 12, 15] . COX-2 generates ROS in various circumstances. On the other hand, ROS increase the expression and activity of COX-2 in arteries from ageing, diabetic and hypertensive rats [9, 10, 12] . Moreover, in rat mesangial cells, the oxidative stress was implicated in the COX-2 up-regulation and prostanoids release induced by Ang II [15] . In many pathological conditions, such as hypertension and diabetes, increased ROS generation is associated with reduction in endothelial NO and the development of endothelial dysfunction. Indeed, when we analyzed the modulatory effect of NO by incubation of MRA with L-NAME, we found that acetylcholine-induced vasodilation was reduced and noradrenaline vasoconstriction was potentiated in both O-CR and O-DR, but O-DR showed a lower NO modulation when compared to O-CR. In addition, incubation with the permeable superoxide dismutase mimetic tempol potentiated acetylcholine-induced relaxation and decreased noradrenaline-induced contraction only in MRA from O-DR. As increased superoxide generation can result in enhanced NO inactivation, these results suggest that the increased degradation of NO by superoxide anions may contribute to the vascular changes in O-DR MRA. In losartan-treated O-DR, tempol failed to modify acetylcholine and noradrenaline responses while L-NAME decreased acetylcholine relaxation and potentiated vasoconstriction to noradrenaline in a similar manner to that observed in O-CR. These functional results are consistent with decreased superoxide generation and enhanced NO bioavailability in O-DR MRA after losartan treatment. Consequently, and considering these results, we can conclude that the COX-2 overexpression in arteries from O-DR may involve increased oxidative stress. Here, we cannot elucidate the mechanism by what losartan improves insulin sensitivity in O-DR and decreases COX-2 expression. However, the fact that Ang II is a potent pro-inflammatory mediator and that inflammatory markers is increased in offspring of hyperglycaemic mothers [30, 31] , suggests a potential role for Ang II as an insulin resistance and endothelial dysfunction inducer in O-DR. At the vascular level, this Ang II-dependent inflammatory process seems to be characterized, at least in part, by a COX-2 overexpression and increased oxidative stress, which in turn may contribute to increased peripheral vascular resistance and BP in O-DR.
There are several limitations of the present study that should be mentioned. In our O-DR, BP and insulin resistance were significantly increased, and these parameters were reduced by chronic losartan administration. A possible interpretation of the present results is that the endothelial dysfunction present in O-DR is due to increases in BP and/ or insulin resistance and that COX-2-dependent endothelial dysfunction is reversed by losartan administration at least in part through a lowering of these parameters. In fact, evidence of endothelial dysfunction has been observed in several vessels in states of elevated BP and insulin resistance [10] [11] [12] [13] . However, it is important to mention that in O-DR, the increment in COX-2 expression precedes the BP elevation [6] , suggesting that it could be involved in the genesis of hypertension in these rats. Another question is whether the beneficial effects of losartan on the O-DR MRA are shared by others resistance vessels. Finally, as we used the entire blood vessel for western blots, we are unable to determine the cell types where COX-2 is expressed. Therefore, further studies will be required to investigate these points.
Conclusions
In summary, the present results reveal that chronic losartan administration in O-DR normalizes endothelial function in MRA by correcting the existing COX-2 overexpression, increased oxidative stress and the imbalance between endothelium-derived relaxing and contracting factors. These findings not only support the beneficial effects of AT 1 R antagonist in O-DR, but also suggest the implication of Ang II as a putative mediator of hyperglycemia-programmed vascular dysfunction in rats.
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